BioPharmSignal logoBioPharmSignal

Biotech News

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MannKind (MNKD)MannKindConference / presentation

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36 th Annual Healthcare Life Sciences

Open original release

Related news

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MNKDMannKind2026-03-09 13:05 EST

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-05-27 12:00 EST

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

EMBCEmbecta2025-12-18 22:00 EST

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

ETNB89bio, Inc.2025-06-04 20:05 EST

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

EMBCEmbecta2026-05-08 13:00 EST

embecta to Participate at the 2026 BofA Securities Global Health Care Conference

NAMSNewAmsterdam Pharma2026-04-08 12:00 EST

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

MISTMilestone Pharmaceuticals Inc.2026-04-07 12:30 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

View all latest news

MannKind

MannKind is a specialty pharmaceutical company best known for Afrezza and inhaled therapeutic delivery. The company has worked to build a broader inhaled-platform story around respiratory and diabetes care.

Recent company news

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MNKDMannKind2026-05-29 18:00 EST

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MNKDMannKind2026-05-29 16:30 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MNKDMannKind2026-05-27 13:05 EST

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States